A downtrend has been apparent in Veru Inc. (VERU) lately. While the stock has lost 5.2% over the past week, it could witness ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, clinical trial experts and doctors say they may also need to demonstrate ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

$VERU insiders have traded $VERU stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales. Here’s a ...

In another example of the volatility facing developers of obesity drugs, Veru saw its share price cut nearly in half – despite reporting ostensibly positive data for a drug candidate.

Novel enobosarm modified release oral formulation Veru is currently developing a novel, patentable, modified release formulation for enobosarm. We anticipate the actual formulation ...

At Veru Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have report no sales in the last 30 days, meanwhile, insiders have reported buying a total of 150.00K ...

A downtrend has been apparent in Veru Inc. (VERU) lately. While the stock has lost 5.2% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last ...

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development ...